Noticias destacadas
![](https://iqs.edu/app/uploads/2024/03/noticia-iqs-projecte-mnkimmunonco-gqf.jpg)
Nuevo inhibidor MNK contra la resistencia a terapias de cáncer
![](https://iqs.edu/app/uploads/2024/03/noticia-iqs-2023-11-20-fundacio-empreses-acte-institucional-takasago-001.jpg)
Takasago, nueva empresa de Fundación Empresas IQS
![](https://iqs.edu/app/uploads/2024/03/noticia-iqs-2023-11-07-inke-fundacio-empreses-002.jpg)
Inke, nueva empresa de la Fundación Empresas IQS
![](https://iqs.edu/app/uploads/2024/03/noticia-iqs-gemat-lab-biomaterials-2021-006.jpg)
Manifiesto de soporte al modelo de transferencia TECNIO
![](https://iqs.edu/app/uploads/2024/03/noticia-biospain_iqs.jpg)
IQS Tech Tranfer, presente en BIOSPAIN
![](https://iqs.edu/app/uploads/2024/03/noticia-immutol_kickoff.jpg)
Nuevas terapias efectivas para la esclerosis múltiple
![](https://iqs.edu/app/uploads/2024/03/noticia-iqs-fuentesalz-sara-2023-las7de-001.png)
Dra. Sara Fuentelsaz, investigadora postdoctoral del grupo GEVAB
Consulta nuestros próximos eventos
![](https://iqs.edu/app/uploads/2024/01/around-street.png)